Macro concerns overshadowed ESG developments during the February reporting season, but there was plenty to report: decarbonisation continued apace; green commodities entered rocky water but other revenue-generating projects progressed; and regulators took aim
While coal prices have started to retreat after a strong rally, New Hope Corp’s capital expenditure plans should see the company boost production
In newly released research, two brokers express a preference for Stanmore Resources over Coronado Global Resources
A glance through the latest expert views and predictions about commodities: outlooks for iron ore, steel and copper
A takeover bid for Healius by Australian Clinical Labs has been greeted with very little enthusiasm, if any
Michael Gable of Fairmont Equities suggests the technicals are indicating the ASX200 has become oversold, suggesting a bounce is possible
Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development
After a recent tour of Macquarie Group’s operations in the Americas, brokers highlight the growing opportunity in the region
FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments
Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech’s treatment of Rett syndrome
